Evaluation of the Efficacy and Tolerability of Nebivolol versus Lisinopril in the Treatment of Essential Arterial Hypertension: A Randomized, Multicentre, Double-blind Study

References

• Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d-and 1-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259–64.
   Google Scholar
• Gao YS, Nagao T, Bond RA. Nebivolol induces endothe-lium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964–9.
   Google Scholar
• Broeders MAW, Doevendans PA, Bekkers BCAM, et al. Nebivolol: a third-generation fl-blocker that augments vascular nitric oxide release. Endothelial #2-adrenergic receptor-mediated nitric oxide production. Circulation 2000; 102: 677–82.
   Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067–71.
   PubMed Web of Science ®Google Scholar
• Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A rando-mised, double blind crossover study. Circulation 2001; 104: 511–14.
   Google Scholar
• Andre DE, Arnet U, Yang Z, Luscher TF. Nebivolol inhibits human aortic smooth muscle cell growth: effects on cell cycle regulatory proteins. J Cardiovasc Pharmacol 2000; 35: 845–8.
   PubMedGoogle Scholar
• Van Nueten L, Dupont AG, Veertommen C, Goyvaerts H, Robertson JI. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997; 11: 139–44.
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Lefebvre J, Poirier L. A double blind crossover comparison of nebivolol and lisinopril in treat-ment of ambulatory hypertension. Am J Therap 1994; 1: 74–80.
   Google Scholar
• Guidelines Subcommittee. 1999 World Health Organiza-tion-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–83.
   Google Scholar
• McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633–51.
   PubMed Web of Science ®Google Scholar
• Cleophas TJ, Grabowsky I, Niemeyer MG. Long-term efficacy of nebivolol monotherapy in patients with hyper-tension. Curr Ther Res 2001; 62: 451–61.
   Google Scholar
• Binstock ML, Franklin KL. A comparison of compliance techniques on the control of high blood pressure. Am J Hypertens 1988; 1: 192–4S.
   PubMed Web of Science ®Google Scholar
• Stason WB. Opportunities to improve the cost-effectiveness of treatment for hypertension. Hypertension 1991; 18 Suppl:: 1161–6.
   Google Scholar
• Weber MA. Strategies for improving blood pressure control. Am J Hypertens 1998; 11: 897–9.
   PubMedGoogle Scholar
• Van Bortel LM, Breed JG, Joosten J, Kragten JA, Luster-mans FA, Mooij JM. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856–62.
   Google Scholar
• Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomized trial. J Hum Hypertens 1997; 11: 813–19.
   Google Scholar
• Van Nueten L, Rishoj Nielsen M, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs. enalapril in essential hypertension: a long-term double blind comparative trial. Acta Clin Belgica 1999; 54: 19–25.
   Google Scholar
• Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs. atenolol and placebo in essential hypertension: a double blind randomized trial. J Hum Hypertens 1998; 12: 135–40.
   Google Scholar
• Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753–7.
   PubMed Web of Science ®Google Scholar
• Van Nueten L, Lacourciere Y, Vyssoulis G, et al. Nebivolol vs. nifedipine in the treatment of essential hypertension: a double blind, randomised, comparative trial. Am J Ther 1998; 5: 237–43.
   Google Scholar
• Lacourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32: 660–6.
   Google Scholar
• Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorotiazide alone or in combination. A randomised, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994; 7: 137–45.
   Google Scholar